Treats relapsing forms of multiple sclerosis (MS). ANDA 209668, held by Zydus Pharms. Teriflunomide.
As of Nov 16, 2026, ANDA 209668 (Teriflunomide), held by Zydus Pharms, was first approved by FDA on Nov 30, 2018, with 0 approved supplements and 0 published complete response letters.
Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 30, 2018 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters